ArticleJournal of Alzheimer's disease reports
Pre-pilot study: Reactivating brain waste clearance via vasopressin fragment-A novel approach to Alzheimer's disease therapy.
Article in Journal of Alzheimer's disease reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Impaired clearance of amyloid-β (Aβ) and other metabolic waste products has been implicated in Alzheimer's disease (AD). Arginine vasopressin (AVP) fragments have been associated with memory-related effects and may influence glymphatic-related pathways. Objective: This pre-pilot exploratory study investigated the potential effects of an AVP (4-9) fragment analog on Aβ-related biomarkers and cognitive function. Methods: Seven participants (three healthy adults and four individuals with AD) received intranasal administration of an AVP (4-9) fragment analog for two weeks at a daily dose of 60 ng. Aβ-related burden was assessed using blood-based Composite Biomarker (CB) values reported to correlate with amyloid PET findings. Cognitive function in AD participants was evaluated using the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog). Results: At baseline, CB values were 5- to 20-fold higher in individuals with AD than in healthy adults. Following treatment, mean CB values in the AD group decreased by 36%, with comparable relative reductions observed across groups. ADAS-Cog scores improved by a mean of 8.1 points over two weeks. No adverse events were observed. Conclusions: AVP (4-9) fragments may influence cognitive processes and glymphatic-related pathways. These findings should be interpreted cautiously given the small sample size and open-label design but may provide a basis for future controlled investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.